• PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma

    13 days ago - By Journal of Pediatric Surgery

    : Novel therapies are needed for patients with hepatoblastoma due to an increasing incidence of disease and poor prognosis for advanced, refractory, and recurrent disease. PIM kinases promote tumorigenesis in hepatoblastoma. A novel PIM inhibitor, PIM447, has shown promise in inhibiting oncogenesis in hematologic and lymphoid malignancies. We hypothesized that PIM inhibition with PIM447 would result in decreased tumorigenesis in hepatoblastoma.
    Read more ...